Monthly Healthcare Review February 2017 Company Name Last Financing Date HQ Location Description Last Financing Size (Millions) Lead Manager PCL (SG Cap Technology) (241820) 23-Feb-17 Geumcheon- gu, South Korea Developer of a protein micro-array platform to screen HIV, HCV, HBV and other infectious diseases. 12.59 Korea Investment & Securities Oncopeptides (ONCO) 22-Feb-17 Stockholm, Sweden Developer of an anti-cancer drug that has the ability to achieve higher concentrations of cancer killing molecules in cancer cells without a corresponding increase in damage to the patient's bone marrow. 73.08 ABG Sundal Collier, Carnegie Investment Bank, DNB Markets The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month. IPOs Compiled by: Morgan Reape Source: Pitchbook 1
Transcript
Monthly Healthcare Review
February 2017
Company NameLast Financing
DateHQ Location Description
Last
Financing
Size
(Millions)
Lead Manager
PCL (SG Cap
Technology) (241820) 23-Feb-17
Geumcheon-
gu, South
Korea
Developer of a protein micro-array platform to screen HIV, HCV, HBV and other
infectious diseases. 12.59
Korea Investment
& Securities
Oncopeptides (ONCO) 22-Feb-17
Stockholm,
Sweden
Developer of an anti-cancer drug that has the ability to achieve higher concentrations of
cancer killing molecules in cancer cells without a corresponding increase in damage to the
patient's bone marrow. 73.08
ABG Sundal Collier,
Carnegie
Investment Bank,
DNB Markets
The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.
IPOs
Compiled by: Morgan Reape
Source: Pitchbook 1
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Muse Bio 28-Feb-17 Boulder, CO Early Stage VC
Developer of a genome engineering technology designed to enable high
throughput massively-multiplexed CRISPR editing of proteins, pathways
and genomes. 23.00 Venrock
Motus GI Medical
Technologies 28-Feb-17 Nazareth, Israel Later Stage VC
Developer of a single-use endoscopy device that attaches to a standard
colonoscope and creates turbulence within the colon using water jets,
enabling physicians to clean, visualize, diagnose and, if necessary, treat an
Provider of a non-invasive cardiac magnetic resonance imaging analysis
software created for early diagnosis of diseases. 0.23
Undisclosed
Investors
Addex Therapeutics
(ADXN) 28-Feb-17
Geneva,
Switzerland PIPE
Developer of an allosteric modulator drug discovery platform created to
offer biopharmaceutical products for the treatment of neurological
disorders. 3.00
Herculis Partners,
Undisclosed
Investors
SynGen 27-Feb-17 Sacramento, CA Later Stage VC
Developer of single use disposable cartridges to capture stem and
progenitor cells from peripheral and umbilical cord blood, bone marrow
and adipose tissue. 3.00
Undisclosed
Investors
Pierre Guérin 27-Feb-17
Mauzé-sur-le-
Mignon, France
PE Growth/
Expansion
Manufacturer of engineered industrial products, such as stainless steel
tanks and bioreactors. Undisclosed Capzanine
Pharma Two B 27-Feb-17 Rehovot, Israel Later Stage VC Developer of drugs for the treatment of Parkinson's disease and cancer. 30.00 Israel Biotech Fund
Neolight 27-Feb-17 Scottsdale, AZ Angel
Developer of phototherapy beds to cure jaundice in pre-term and full-term
babies. 1.00
Undisclosed
Investors
MyoTherix 27-Feb-17 Union City, CA Early Stage VC
Developer of therapeutics for Duchenne muscular dystrophy and other
muscle disorders. 8.43
Undisclosed
Investors
Kinnos 27-Feb-17 Brooklyn, NY Seed Round
Developer of an infectious disease decontamination method using a
powdered additive for disinfectants, enabling healthcare workers and
patients to prevent disease outbreak through clothing and other surfaces. 1.00
Georgica Advisors,
New York Angels,
Venture Well
Illustris Pharmaceuticals 27-Feb-17 Palto Alto, CA Early Stage VC
Developer of molecule delivery technology designed to deliver ingredients
that can permeate tissue structures. 5.00
Undisclosed
Investors
Exonics Therapeutics 27-Feb-17 Boston, MA Seed Round
Developer of a gene editing treatment created to find a cure for Duchenne
muscular dystrophy. 5.00
CureDuchenne
Ventures
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Compiled by: Morgan Reape
Source: Pitchbook 2
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Congenica 27-Feb-17
Cambridge, United
Kingdom Early Stage VC
Developer of a clinical genome analysis platform that processes genome
wide data sets to detect mutations by filtering clinically relevant variants
and deep clinical phenotyping, enabling clinicians to provide actionable
interpretation of genetic disease for patients. 9.99
Cambridge
Innovation Capital
Xenex Disinfection
Services 24-Feb-17 San Antonio, TX Later Stage VC
Developer of a portable device that uses pulsed xenon UV light to kill
bacteria and viruses in healthcare facility rooms. 38.00 Essex Woodlands
Samark Technology 24-Feb-17 Sarasota, FL Angel
Developer of micro-invasive video needle syringes intended to visualize
orthopedic surgeries. 0.10
Undisclosed
Investors
RapidConnect 24-Feb-17 Raleigh, NC Angel
Developer of a mobile app and Web interface designed by physicians
enabling real-time secure communications between the clinical care team. 0.77
Undisclosed
Investors
Lung Therapeutics 24-Feb-17 Austin, TX Early Stage VC
Developer of pharmaceutical products targeting niche, orphan drug
indications for lung injury and disease with an emphasis on fibrosis. 3.48
UT Horizon Fund,
Undisclosed
Investors
Inprentus 24-Feb-17 Champaign, IL Early Stage VC
Developer of ultrahigh precision diffraction gratings for X-Ray analysis
and imaging. 0.54
Serra Ventures,
Undisclosed
Investors
CardioSolv Ablation
Technologies 24-Feb-17 Baltimore, MD Angel
Developer of a heart simulation software that guides therapies for the
treatment of patients with ventricular tachycardia. 0.05
Undisclosed
Investors
Agilis Biotherapeutics 24-Feb-17 Cambridge, MA Early Stage VC
Developer of DNA-based therapeutics using the transformative approach
based on delivering a corrected copy of a naturally occurring gene directly
to targeted cells designed to provide long-term efficacy for patients with
debilitating, often fatal, rare genetic diseases that affect the central nervous
system. 12.67
Undisclosed
Investors
Qool Therapeutics 23-Feb-17 Menlo Park, CA Early Stage VC
Provider of a non-invasive system to induce therapeutic hypothermia for
preservation of tissue following a heart attack, stroke and traumatic brain
injury. 6.70
Western Technology
Investment
Fusion Pharmaceuticals 23-Feb-17 Hamilton, Canada Early Stage VC
Developer of novel targeted alpha therapeutics for chemotherapy resistant
cancers created to leverage radioactivity in relatively low doses to attack
cancer cells. 25.00
Johnson & Johnson
Innovation
Compiled by: Morgan Reape
Source: Pitchbook 3
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Front Range
Biosciences 23-Feb-17 Boulder, CO Seed Round
Provider of known agricultural biotechnologies such as tissue culture,
cryopreservation, genomics, and marker-assisted breeding to enable
cannabis cultivators to improve their yields, reduce disease, and create
novel strains. 1.50
Intuitive Private
Equity, Salveo
Capital, Sand Hill
Angels
Theragen 22-Feb-17 Manassas, VA Early Stage VC
Developer of medical devices to treat osteoarthritis and apply therapeutic
energy technologies for healing and pain relief. 9.14
Ballast Point
Ventures,
Undisclosed
Investors
PMV Pharmaceuticals 22-Feb-17 Cranbury, NJ Early Stage VC
Developer of small molecule drugs that induce an organized program of
cellular death, enabling cancer patients to restore the body's natural
defense mechanism and prevent the proliferation of potentially cancerous
cells. 73.73
Topspin Ventures,
Euclidean Capital
PharmacoPhotonics 22-Feb-17 Carmel, IN Angel
Developer of detection devices providing a measure of the kidney's
function or glomerular filtration rate in 15 to 30 minutes, enabling
hospitals, cardiac catheterization labs and physician to treat acute kidney
injuries and chronic kidney diseases. 3.00
Undisclosed
Investors
Oncternal Therapeutics 22-Feb-17 San Diego, CA Early Stage VC Developer of novel therapies for both rare and common cancers. 18.40
Undisclosed
Investors
InSilico Medicine 22-Feb-17 Baltimore, MD Early Stage VC
The company uses deep learning technology for drug discovery and drug
re-purposing for aging and age-related diseases, allowing for the
identification of molecules that may be effective against a variety of
cancers as well as metabolic, cardiovascular and central nervous system
diseases. 10.00
Undisclosed
Investors
Imago BioSciences 22-Feb-17 San Francisco, CA Early Stage VC
Provider of a treatment designed to translate state-of-the-art science into
novel medicines for the treatment of cancer and other diseases of gene
expression. 40.50 Clarus Ventures
BookDoc 22-Feb-17
Petaling Jaya,
Malaysia Seed Round
Provider of an integrated online ecosystem for local and overseas health
travelers. 2.00
Undisclosed
Investors
Compiled by: Morgan Reape
Source: Pitchbook 4
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
Developer of therapeutics targeting cell lineage-specific tumor proteins
that maximize both anti-tumor activity and safety in patients with critically
unmet medical needs. 17.00
Black Beret Life
Sciences
Vault Dragon 20-Feb-17
Singapore,
Singapore Seed Round
Provider of a leading clinic management system designed to manage
medical records. 1.16
Golden Equator
Capital, Raging Bull
Realist Pharma 20-Feb-17 Toronto, Canada Early Stage VC
Developer of cell therapies and cancer vaccines through active immune
strategies that utilize the patient's own immune defenses to target
widespread tumor markers present in a large number of cancers. 0.20
Undisclosed
Investors
Compiled by: Morgan Reape
Source: Pitchbook 5
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
QRepublik 20-Feb-17 Moscow, Russia
Accelerator/
Incubator
Developer of a wearable medical device designed to track contact
information about patients and notify their family members about their
location during medical emergencies. 0.35
Russian Venture
Company
Pacifica Labs 20-Feb-17 San Francisco, CA Seed Round
Developer of a mental health application based on Cognitive Behavioral
Therapy with relaxation and wellness techniques that are distilled down
into simple, quick, daily activities to provide a way for people to track their
progress, helping them address stress, anxiety and depression at a gradual
pace. Undisclosed
LEO Innovation
Lab
Modus Therapeutics 20-Feb-17 Stockholm, Sweden Later Stage VC
Developer of an anti-adhesive and anti-inflammatory drug designed
through a chemical depolymerization of heparin that can be used in
treatment of acute painful crisis in sickle cell disease patients. 3.60
Karolinska
Development
iScribes 20-Feb-17 Durham, NC Angel Provider of virtual medical scribe services. 1.11
Undisclosed
Investors
CrowdMed 20-Feb-17 San Francisco, CA Early Stage VC
Provider of an online medical community that offers a collaborative
approach for solving complex medical cases for patients who have been
suffering from unresolved, chronic symptoms for months or even years,
enabling patients to explore all possible medical diagnoses and services. Undisclosed
Arab Angel, Mindset
Ventures
CrossTx 20-Feb-17 Bozeman, MT Early Stage VC
Provider of a cloud-based healthcare coordination platform designed to
improve overall patient experience. 0.74 Frontier Fund 2
Voxello 17-Feb-17 Coralville, IA Early Stage VC
Developer of a suite of input devices such as microphones, proximity
switches, infrared detectors, pressure switches with proprietary software
and a communication device called Noodle, enabling hospitalized patients
to communicate with their caregivers. 1.20
Dakota Venture
Group, Wellmark
Blue Cross and Blue
Shield of Iowa
Hennepin Life Sciences 17-Feb-17 Plymouth, MN Angel
Provider of naturally-derived anti-infective compounds for the prevention
and treatment of infectious diseases, including vaginal candidiasis, urinary
tract infections and skin and soft tissue infections. 1.85
Undisclosed
Investors
Compiled by: Morgan Reape
Source: Pitchbook 6
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Empire Medicinals 17-Feb-17 Rochester, NY Angel
Developer of organic natural products, herbal medicinal products and
natural health and medicinal supplements primarily made from medicinal
mushrooms that help in supporting the immune system health, vitality and
stamina and also helps to manage stress effectively. 0.01
Undisclosed
Investors
DiFusion Technologies 17-Feb-17 Austin, TX Angel
Developer of metallic ion therapeutic agents technology designed for
antimicrobial, cellular repair, tissue regeneration, bone growth, scaffold
construction and increased angiogenesis. 2.43
Undisclosed
Investors
Cyrus Biotechnology 17-Feb-17 Seattle, WA Early Stage VC
Provider of an easy-to-use version of rosetta interface that offers protein
structure prediction and protein designing, enabling its users in molecular,
homology and protein modeling. 1.58
WRF Capital,
Undisclosed
Investors
Xcell Biosciences 16-Feb-17 San Francisco, CA Early Stage VC
Developer of research tools and diagnostic solutions that replicate
physiologically relevant conditions, empowering researchers and drug
developers in transfection and gene editing efficiencies in primary cell
populations for regenerative medicine and cell-based therapy applications. 12.00
HBM Healthcare
Investments
Nativis 16-Feb-17 Seattle, WA Angel
Developer of a non-invasive and non-thermal medical device for the
treatment of solid tumors. 9.62
Undisclosed
Investors
Keriton 16-Feb-17 Philadelphia, PA Seed Round
Provider of breast-milk management and analytics software for neonatal
ICUs, designed to improve nurse productivity and increase expression of
breast milk in lactating mothers. 1.00 BioAdvance
F1 Oncology 16-Feb-17 San Diego, CA Early Stage VC
Owner and operator of a biotechnology company specializing in T-cell
immunotherapy research for developing drugs to treat cancer induced
viruses and antigens. 44.00
F1 BioVentures,
Bridgewest Group,
Sinobioway Group,
SunTerra Capital,
Undisclosed
Investors
Compiled by: Morgan Reape
Source: Pitchbook 7
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Checkmate
Pharmaceuticals 16-Feb-17 Cambridge, MA Early Stage VC
Developer of cancer immunotherapies designed to combine the ability of
CpG DNA to activate an anti-tumor T-cell response with checkpoint
inhibition to overcome a tumor's ability to mute the immune response,
enabling treatment of patients with advanced cutaneous melanoma. 25.00
Sofinnova Ventures,
venBio, Undisclosed
Investors
Surrozen 15-Feb-17
South San
Francisco, CA Early Stage VC
Developer of regenerative drugs that accelerate the repair and renewal of
human tissues through signal transduction pathways. 33.00 The Column Group
Orreco 15-Feb-17 Los Angeles, CA Later Stage VC
Provider of bio-marker analysis intended to optimize athlete performance,
enabling players to reduce the incidence of illness and injury. 2.00 True Ventures
OncoMark 15-Feb-17 Dublin, Ireland Later Stage VC
Developer of a device that detects early stage breast cancer, enabling
clinicians to determine treatment options for their patients. 2.24
Kernel Capital, Irrus
Investments, Halo
Buisiness Angel
Network
Omage Labs 15-Feb-17 Seattle, WA Angel
Provider of a healthcare and wellbeing management platform intended to
track and manage the health of senior citizens. 0.03
Undisclosed
Investors
mClinica 15-Feb-17
Singapore,
Singapore Later Stage VC
Provider of data, analytics and patient engagement tools designed to unite
multinational pharmaceutical companies, governments, NGOs, and
academic institutions on a common platform, provide access to new
sources of data, and allow for the deployment of data-driven programs. 6.30 Iunitus Impact
Luma Therapeutics 15-Feb-17 Millbrae, CA Angel
Developer of light therapies designed to treat inflammatory skin disorders,
such as psoriasis. 2.05
Undisclosed
Investors
Jecure Therapeutics 15-Feb-17 San Diego, CA Early Stage VC
Developer of small-molecule therapeutics for the treatment of non-
alcoholic steatohepatitis and liver fibrosis. 20.00 Versant Ventures
GluSense 15-Feb-17 Rehovot, Israel Later Stage VC
Developer of a minimally invasive device that offers accurate glucose
measurement for a full year with significantly fewer blood glucose
calibrations. 0.54 T1D Fund
Compiled by: Morgan Reape
Source: Pitchbook 8
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Encoda 15-Feb-17 Blue Bell, PA Angel
Developer of a medical revenue cycle automation tool that offers back
office staff with features such as revenue collection and management,
client billing systems, medical insurance claim handling and other similar
services. 1.50
Undisclosed
Investors
Carmat (ALCAR) 15-Feb-17
Vélizy Villacoublay
CEDEX, France PIPE
Designer and developer of a bio-compatible, auto-regulated artificial heart
designed to be as close as possible to the human heart. 31.89 AMF
Caerus Discovery 15-Feb-17 Manassas, VA
Accelerator/
Incubator
Developer of antibody and therapeutic products for the treatment of
human diseases, including infectious, inflammatory, metabolic, neurological
and malignant diseases. 0.05
Prince William
Science Accelerator
Avenu Medical 15-Feb-17
San Juan
Capistrano, CA Later Stage VC
Developer of an innovative, image-guided, single catheter system used to
percutaneously create an arteriovenous fistula for hemodialysis access,
enabling physicians to treat patients with chronic kidney diseases. 13.11
Undisclosed
Investors
Audio Bionics
International 15-Feb-17 Los Angeles, CA Angel
Provider of tinnitus sound therapy intended to effectively suppress
tinnitus. 0.86
Undisclosed
Investors
3D Vision Systems 15-Feb-17 Ann Arbor, MI Angel Manufacturer of medical equipment and supplies. 0.10
Undisclosed
Investors
Updox 14-Feb-17 Dublin, OH Later Stage VC
Provider of a healthcare CRM connectivity platform designed to find
pragmatic ways for providers to adapt to the changing healthcare
landscape. 11.20
Undisclosed
Investors
Tryton Medical 14-Feb-17 Durham, NC Later Stage VC
Developer of a novel cobalt chromium stent system that offers a dedicated
strategy to deploy the side branch artery using a standard single wire
balloon-expandable stent delivery system, enabling its clients to treat
bifurcation lesions in coronary artery diseases. 4.00
Undisclosed
Investors
Sense.ly 14-Feb-17 San Francisco, CA Early Stage VC
Developer of a patient engagement platform that leverages video, voice
and body recognition, sensor integration and augmented reality to enable
continuous monitoring and analysis of patient's health after a discharge. 8.00
Mayo Clinic,
Chengwei Capital
Q Care International 14-Feb-17 Marietta, GA Angel Developer of needle removal and disposal systems. 3.85
Undisclosed
Investors
Compiled by: Morgan Reape
Source: Pitchbook 9
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
HemoSonics 14-Feb-17 Charlottesville, VA Angel
Developer of a point-of-care diagnostic platform that offers actionable
information to guide the management of critical bleeding and clotting. 22.63
Undisclosed
Investors
Treos Bio 13-Feb-17
London, United
Kingdom Early Stage VC
Developer of immunotherapy vaccines intended for the destruction of
cancer cells. 8.00
BXR Group,
Undisclosed
Investors
SigTuple 13-Feb-17 Bangalore, India Early Stage VC
Developer of hardware and software on artificial intelligence technology
designed to digitize pathological tests. 5.80 Accel Partners
Retriever Medical
Dental Payments 13-Feb-17 Valhalla, NY
PE Growth/
Expansion
Provider of healthcare payment solutions allowing providers to integrate
payment processing workflow and data with their existing practice
management software or ERP systems. Undisclosed TA Associates
Hygieia 13-Feb-17 Ann Arbor, MI Later Stage VC
Developer of a diabetes insulin guidance system created to enhance and
simplify insulin therapy. 0.57
Blue Cross Blue
Shield of Michigan
Forerunner Medical 13-Feb-17 Shanghai, China Later Stage VC
Developer and manufacturer of medical devices created on low
temperature radio-frequency ablation and domestic clinical data that are
used for the treatment of cancer in liver, lung, thyroid, breast and other
organs. Undisclosed
Medtronic, Sequoia
Capital China
AltheaDx 13-Feb-17 San Diego, CA Later Stage VC Developer of a pharmacogenetics product testing portfolio. 6.00
Undisclosed
Investors
UAS Laboratories 10-Feb-17 Wausau, WI
PE Growth/
Expansion
Manufacturer of semi-finished and raw-material supplies of probiotic-
based supplements. 21.25
Undisclosed
Investors
SynergEyes 10-Feb-17 Carlsbad, CA Later Stage VC
Provider of hybrid contact lenses for eye conditions like astigmatism,
presbyopia, myopia, hyperopia and keratoconus that are made by
combining new high-Dk materials and vision-optimized designs. 3.53
Undisclosed
Investors
GeneCast
Biotechnology 10-Feb-17 Beijing, China Early Stage VC
Provider of a DNA sequencing platform that offers individual drug
selection and gene detection, efficacy monitoring and liquid biopsy for the
detection of circulating tumor DNA of lung, colon, liver and breast
cancers. 18.00 Tshinghua Holdings
ZSX Medical 9-Feb-17 Philadelphia, PA Later Stage VC
Developer of Zip-stitch, a surgical closure system that is an alternative to
sutures for major surgeries. 1.58
Keiretsu Forum,
Undisclosed
Investors
Compiled by: Morgan Reape
Source: Pitchbook 10
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
VIA Global Health 9-Feb-17 Seattle, WA
Accelerator/
Incubator
Provider of an e-commerce and logistics platform designed to connect
medical distributors with affordable medical devices and supplies. 0.15 500 Startups
Trainer Rx 9-Feb-17 Walnut Creek, CA Early Stage VC
Developer of a medical software designed for healthcare providers who
treat musculoskeletal injury that delivers individualized rehabilitation and
recovery pathways with step-by-step guidance from injury through
recovery. 3.86
Undisclosed
Investors
Therapydia 9-Feb-17 Mill Valley, CA Early Stage VC
Operator of an online community intended to connect physical therapists,
facilitate the exchange of ideas and mobilize physical therapy around key
issues like reimbursement and direct access. 8.92
Peterson Partners,
de Anda Capital,
David Brown
OrthoSera 9-Feb-17
Krems an der
Donau, Austria Early Stage VC
Developer of serum-based orthobiologics created to provide treatment of
dental and musculoskeletal indications. Undisclosed FastVentures
Nanospectra
Biosciences 9-Feb-17 Houston, TX Later Stage VC
Developer of AuroLase Therapy which combines the unique physical and
optical properties of AuroShell particles with a near infrared laser source to
thermally destroy cancer tissue without significant damage to surrounding
healthy tissue. 2.03
Undisclosed
Investors
MolecularMD 9-Feb-17 Portland, OR Later Stage VC
Provider of molecular diagnostic products and services to support clinical
development, regulatory approval and commercialization of targeted
cancer therapies. 2.07
ClearWell Group,
Undisclosed
Investors
Intelligent
Fingerprinting 9-Feb-17
Cambridge, United
Kingdom Later Stage VC Developer of a portable fingerprint-based drug screening system. 3.64
Undisclosed
Investors
Flow Forward Medical 9-Feb-17 Olathe, KS Later Stage VC
Developer of the Arteriovenous Fistula Eligibility system, a small,
temporary, external blood pump designed to stimulate flow-mediated vein
dilation, enabling hemodialysis patients to reduce morbidity and mortality. 7.00
Undisclosed
Investors
Evotec (EVT) 9-Feb-17 Hamburg, Germany PIPE
Developer of drugs in the areas of neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. 96.18 Novo
Biomarker.io 9-Feb-17 San Francisco, CA
Accelerator/
Incubator
Provider of a digital health platform designed to track and decode impact
of dietary changes on health and performance. 0.15 500 Startups
Compiled by: Morgan Reape
Source: Pitchbook 11
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Avails Medical 9-Feb-17 Menlo Park, CA Early Stage VC
Developer of non-invasive therapeutic drug monitoring devices to
determine optimum drug dosage in epileptic patients. 6.86
Developer of drug delivery copolymers created to meet clinical needs in
the fields of orthopedics and arthritis. 0.32
Undisclosed
Investors
Ambient Clinical
Analytics 9-Feb-17 Rochester, MN Early Stage VC
Developer of patient management and clinical support tools designed to
reduce medical errors for data assimilation, communication and analytics. 3.93
Undisclosed
Investors
Welltrack 8-Feb-17 Fredericton, Canada
Accelerator/
Incubator
Provider of on-demand online therapy for mental health issues specializing
in providing computerized cognitive behavioral therapy for the treatment
of stress, anxiety and depression. Undisclosed 500 Startups
Vitruvian Networks 8-Feb-17 Menlo Park, CA Early Stage VC
Developer of software for scaling and digital services for cell and gene
therapies. 13.81
GE ventures,
Drraper Fisher
Jurvetson, Mayo
Clinic Ventures,
Undisclosed
Investors
Phynd Technologies 8-Feb-17 Dallas, TX Early Stage VC
Provider of a management platform that enables hospitals and health
systems to manage their licensed provider data profiles across all core
clinical, financial and operational IT systems. 0.25
Rex Health
Ventures
Hospi 8-Feb-17 Newark, CA Later Stage VC
Developer of a rectal catheter device designed to facilitate administration
of liquids or medications. 3.49
Undisclosed
Investors
HistoSonics 8-Feb-17 Ann Arbor, MI Later Stage VC
Provider of a histotripsy platform that offers non-invasive, non-thermal
surgery using pulsed sound waves to induce cavitation that mechanically
destroys tissue, tumors and plaque at the cellular level. 8.26
Undisclosed
Investors
Genomind 8-Feb-17 King of Prussia, PA Later Stage VC
Developer of personalized medicines created to advance mental healthcare
through genetic testing. 11.00
Silicon Valley Bank,
Undisclosed
Investors
Endoshape 8-Feb-17 Boulder, CO Later Stage VC
Developer of polymer-based vascular embolization products with a focus
on the coil embolization and occlusion market. 4.00
Undisclosed
Investors
Compiled by: Morgan Reape
Source: Pitchbook 12
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
Developer of influenza therapy intended to fight against seasonal and
pandemic influenza. Undisclosed
Stichting Participatie
Atriva, High-Tech
Gründerfonds
Applied Therapeutics 8-Feb-17 New York, NY Early Stage VC
Developer of a disease treatment technology platform that offers
opportunities for effective drug development against diseases. 6.07
Alexandria Real
Estate Equities
Vesiflo 7-Feb-17 Redmond, WA Angel
Developer of a replaceable urinary prosthesis that help women suffering
from impaired detrusor contractility to push urine out of the bladder. 2.40
Undisclosed
Investors
Recursion
Pharmaceuticals 7-Feb-17 Salt Lake City, UT Early Stage VC
Operator of a drug discovery company that combines experimental biology
and bioinformatics with artificial intelligence in a massively parallel system
to quickly and efficiently identify treatments for any disease that can be
modeled at the cellular level. 55.10
Lux Capital, Square
1 Bank
Prexton Therapeutics 7-Feb-17
Geneva,
Switzerland Early Stage VC
Developer of medical drugs and therapeutics for brain disorders that offers
an alternative to the stimulation of the dopaminergic system through a
novel molecule mGluR4 PAM series. 30.89
Forbion Capital
Partners, Seroba
Life Sciences
Laminate Medical
Technologies 7-Feb-17 Tel-Aviv, Israel Angel
Developer of a blood vessel support device created for improving renal
vascular procedures. 8.00
Haisco
Pharmaceutical
Group, Undisclosed
Investors
Connexions Asia 7-Feb-17
Singapore,
Singapore Early Stage VC
Provider of an employee benefits and workplace wellness platform for
employees designed to offer a fixed benefits wallet to choose the most
relevant mix of insurance and wellness services from a wide range of
providers to suit their personal needs. 25.00
B Capital Group,
EDB Investments
BrainSpec 7-Feb-17 Boston, MA
Accelerator/
Incubator
Operator of a health technology company created to diagnose brain
disorders using an efficient and radiation-free approach that involves
software and magnetic resonance spectroscopy. 0.12 Techstars
BioMarcK
Pharmaceuticals 7-Feb-17 Durham, NC Later Stage VC
Developer of drugs for the treatment of pulmonary diseases associated
with the over-secretion of mucus and pulmonary inflammation. 7.75
Undisclosed
Investors
Compiled by: Morgan Reape
Source: Pitchbook 13
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Acticor Biotech 7-Feb-17 Paris, France Early Stage VC Provider of therapeutic services for the treatment of emergency stroke. 3.09
Anaxago, ARMESA,
Cap Decisif
Management,
Undisclosed
Investors
ProMetic Life Sciences
(PLI) 6-Feb-17 Laval, Canada PIPE
Developer of therapeutics products for fibrosis, anemia, neutropenia,
cancer and autoimmune disease/inflammation. 21.05
California Capital
Equity
CureApp 6-Feb-17 Tokyo, Japan Early Stage VC
Developer of a disease treatment app created to progress the utilization of
ICT and AI for medical and nursing care. 3.36
Beyond Next
Ventures
Chèque Santé 6-Feb-17 Montpellier, France Early Stage VC
Provider of Web and payment services for the healthcare sector designed
to dedicate health prevention and well-being. 5.54
SORIDEC, iXO
Private Equity
Banyan Biomarkers 6-Feb-17 Alachua, FL Later Stage VC Developer of diagnostic products to detect traumatic brain injuries. 11.40
Undisclosed
Investors
AZTherapies 6-Feb-17 Boston, MA Early Stage VC
Developer of combination drug therapies to prevent and manage disease
progression in persons with early to moderate Alzheimer's disease. 16.05
Undisclosed
Investors
Avalon Healthcare
Solutions 6-Feb-17 Tampa, FL Early Stage VC
Provider of laboratory benefits management services by reducing
unnecessary utilization, optimizing network and increasing scores for
payers through quality improvement. 29.27
Echo Health
Ventures, BlueCross
BlueShield of South
Carolina, Fransisco
Partners,
Undisclosed
Investors
Ark Biosciences 6-Feb-17 Shanghai, China Early Stage VC
Developer of innovative therapeutics created to address unmet medical
needs in the area of respiratory viral infection and viral hepatitis. Undisclosed
Bioventure
Investment
Management
Compiled by: Morgan Reape
Source: Pitchbook 14
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Abbisko Therapeutics 6-Feb-17 Shanghai, China Early Stage VC
Provider of drug research and development services for the treatment of
cancer. 28.00
Lilly Asia Ventures,
Sinopharm Capital,
TF Capital
myNEXUS 3-Feb-17 Brentwood, TN
PE Growth/
Expansion
Provider of healthcare management services that monitor a patient's health
status and generates analytical reports intended to connect individuals to
caregivers. 1.50
Undisclosed
Investors
Comprehend Systems 3-Feb-17 Redwood City, CA Later Stage VC
Provider of a single cloud-based suite that offers real-time patient insights,
on-time milestones and improved data quality with powerful data
aggregation, monitoring, analytics and collaboration capabilities to clinical
trial teams. 14.80 Eminence Capital
Vividion Therapeutics 2-Feb-17 San Diego, CA Early Stage VC
Developer of a novel drug discovery platform that applies chemical
proteomics to expand the druggable proteome and address difficult targets
to bring new, transformative treatments to patients with serious illnesses,
enabling customers to create proteome-wide drug interaction maps for
simultaneous target engagement and global selectivity profiling. 50.00
ARCH Venture
Partners, Versant
Ventures
Tarveda Therapeutics 2-Feb-17 Watertown, MA Later Stage VC
Developer of novel cancer therapies created to treat solid tumors for
patients with neuroendocrine cancers. 30.00 Versant Ventures
Slope.io 2-Feb-17 Chattanooga, TN Seed Round
Provider of specialized, software-driven logistics services to clinical
researchers. 0.90 Vivek Garipalli
Serina Therapeutics 2-Feb-17 Huntsville, AL Angel
Developer of a therapeutics and drug delivery platform based on polymer
technology designed to treat cancer, inflammation, pain and metabolic
disorders. 4.06
Undisclosed
Investors
InnovaTel 2-Feb-17 Erie, PA
PE Growth/
Expansion
Provider of telepsychiatry services intended to increase the accessibility of
psychiatric care in rural areas. 2.00
Canyon Healthcare
Partners
Coriell Life Sciences 2-Feb-17 Camden, NJ Seed Round
Provider of a healthcare management system that offers storage of
genomic data, expert interpretation and an interchange framework that
delivers clinically-relevant genomic interpretation at the point-of-care. 1.20
Undisclosed
Investors
Compiled by: Morgan Reape
Source: Pitchbook 15
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
ApcinteX 2-Feb-17
Cambridge, United
Kingdom Early Stage VC
Developer of an anticoagulant protein that seeks to turn down the activity
of a key natural anticoagulant pathway to produce normal blood clotting in
patients with haemophilia. 17.48
Medicxi Ventures,
Imperial
Innovations Group
VisCardia 1-Feb-17 Beaverton, OR Early Stage VC
Developer of an implantable electronic sensor and electrode system for
delivering chronic electrical stimulation for treating thoracic pressure
augmentation. 0.40
Kinetic Capital
Partners
Sidekick (Health
Behavior Change
Platform) 1-Feb-17
Gothenburg,
Sweden Early Stage VC
Developer of a health engagement and analytics platform that combines
gamified engagement methods with health screening and analytics for the
prevention and treatment of lifestyle related chronic diseases. 1.50 Frumtak Ventures
PointClickCare 1-Feb-17 Mississauga, Canada
PE Growth/
Expansion
Developer of a SaaS cloud-based electronic health records software
designed to help long-term post-acute care and senior living providers
streamline and manage the complete lifecycle of resident care. 85.00
Gdragoneer
Investment Group,
JMI Equity
Immunic Therapeutics 1-Feb-17
Planegg-
Martinsried,
Germany Early Stage VC
Provider and developer of small molecule immune modulators that block
T-helper type 1- and type 17-mediated immune and autoimmune responses
to treat conditions including inflammatory bowel disease and psoriasis. 23.11
LifeCare Partners,
Life Sciences
Partners
HealthReveal 1-Feb-17 New York, NY Early Stage VC
Developer of a cloud-based, clinical analytics platform designed to
continually monitor and analyze patient physiology and care by integrating
multiple real-time streams of clinical, operational and biometric data to
ensure adherence to evidence-based care guidelines by clinicians and
patients. 10.80
GE ventures,
Drraper Fisher
Jurvetson, Mayo
Clinic Ventures,
Undisclosed
Investors
Glide Pharmaceutical 1-Feb-17
Oxfordshire, United
Kingdom Later Stage VC
Developer of needle-free drug delivery platforms focused on solid dose
formulations of therapeutics and vaccines. 4.00
Invesco Perpetual,
Oxford Technology,
Oxford Capital
Partners
Compiled by: Morgan Reape
Source: Pitchbook 16
Monthly Healthcare Review
February 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Lead Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
DVM Systems 1-Feb-17 Greeley, CO Angel
Developer of temperature monitoring equipment that provides accurate
heat and ovulation detection. 0.75
Undisclosed
Investors
CoheroHealth 1-Feb-17 New York, NY Early Stage VC
Developer and provider of a connected healthcare device platform
enabling respiratory patients to use a mobile device to monitor health and
coordination between patients and their care providers. 13.35 Three Leaf Ventures
Allurion Technologies 1-Feb-17 Natick, MA Later Stage VC
Developer of Elipse Balloon, a thin, flexible polymer film that is delivered
in a swallowable capsule, eliminating the need for surgery, endoscopy or
anesthesia, enabling overweight and obese individuals to reduce weight. 25.02 Romulus Capital
Compiled by: Morgan Reape
Source: Pitchbook 17
Monthly Healthcare Review
February 2017
Acquirer Target HQ Location Date DescriptionTransaction
Value (Millions)
Takara Bio USA
Wafergen Bio-
Systems Fremont, CA 28-Feb-17
Operator of a biotechnology company that develops, manufactures and sells
systems for gene expression, genotyping and stem cell research for life sciences,
pharmaceutical drug discovery and diagnostic products industries. 50.00
TIDI Products Posey Arcadia, CA 28-Feb-17
Manufacturer of products for fall management, wound management, bed safety,
seating and positioning to create a safer patient environment. Undisclosed
A2 Acquisition
Medicenna
Therapeutics Vancouver, Canada 27-Feb-17
Developer of novel cytokines for the targeted treatment of cancer, autoimmune
disease and fibrosis. Undisclosed
Johnson & Johnson
Abbott Medical
Optics Santa Ana, CA 27-Feb-17
Manufacturer of intraocular lenses, laser-vision correction systems,
phacoemulsification systems, viscoelastics, microkeratomes and related products
used in cataract and refractive surgeries. 4325.00
Kernel
Kendall Research
Systems Cambridge, MA 24-Feb-17
Developer of hardware instrumentation and software solutions for in vivo
neuroscience research. Undisclosed
Lumenis
Focus Medical
(Laser Business) Bethel, CT 24-Feb-17
Manufacturer of electromedical, electrotherapeutic apparatuses and surgical and
medical instruments. Undisclosed
Integra LifeSciences
Holdings Derma Sciences Princeton, NJ 24-Feb-17 Provider of wound care, wound closure, burn care and skin care products. 204.00
One Call Care
Management High Line Health New York, NY 23-Feb-17
Developer of a healthcare analytics and data visualization platform that distills
large quantities of data into straightforward, actionable reporting. Undisclosed
Aviva Systems Biology GenWay BioTech San Diego, CA 23-Feb-17
Provider of customized products and services including antigen preparation,
antibody development and immunoassays for the research community. Undisclosed
OncoDNA BioSequence Valencia, Spain 23-Feb-17
Provider of cutting edge tumor molecular profiling technologies intended to offer
cancer diagnosis and genomics ultrasequencing services. Undisclosed
My Marijuana Canada Sublime Culture Montreal, Canada 22-Feb-17 Producer of cannabis intended for medical purposes regulations. Undisclosed
Sanitas Healthia Madrid, Spain 21-Feb-17
Developer of digital health services platform software that offers a footprint
Kalytera Therapeutics Talent Biotechs Bnei-Brak, Israel 16-Feb-17
Developer of cannabidiol-based therapies for the treatment of graft versus host
disease. Undisclosed
Takeda Pharmaceutical
Ariad
Pharmaceuticals Cambridge, MA 16-Feb-17
Developer of drugs focused on small molecule medicines that target proteins and
pathways involved in cancer. 5200.00
Mergers and AcquisitionsThe following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous
month.
Compiled by: Morgan Reape
Source: Pitchbook 18
Monthly Healthcare Review
February 2017
Acquirer Target HQ Location Date DescriptionTransaction
Value (Millions)
Mergers and AcquisitionsThe following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous
blood pressure and other related instruments. 330.00
Anatrace
Molecular
Dimensions
Suffolk, United
Kingdom 14-Feb-17
Supplier of screens, reagents and other consumables used by crystallographers
across the world to determine protein structures analysis in structural biology
research. Undisclosed
Symetis
Middle Peak
Medical Palo Alto, CA 14-Feb-17
Developer of a minimally invasive device to restore mitral valve competence in
both functional and degenerative mitral valve disease by providing a new posterior
surface onto which the anterior leaflet can properly seal. Undisclosed
Singapore
eDevelopment iGalen International San Diego, CA 14-Feb-17 Distributor of health supplements intended to control and manage inflammation. Undisclosed
iGambit HealthDatix
Saint Petersburg,
FL 14-Feb-17
Developer of software that performs risk assessment and analysis of patients,
produces patient reports, physician reports and summary reports for billing and
identifies those patients who are at risk for chronic conditions. Undisclosed
Cosmos Holdings Decahedron
Harlow, United
Kingdom 14-Feb-17 Wholesaler of pharmaceutical products. 1.00
PanTheryz APS BioGroup Phoenix, AZ 14-Feb-17 Manufacturer and producer of colostrum products and nutritional supplements. Undisclosed
MiRagen Therapeutics Signal Genetics Carlsbad, CA 13-Feb-17 Provider of molecular diagnostic services for cancer patients. 60.00
Compiled by: Morgan Reape
Source: Pitchbook 19
Monthly Healthcare Review
February 2017
Acquirer Target HQ Location Date DescriptionTransaction
Value (Millions)
Mergers and AcquisitionsThe following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous
month.
Fitesa Pantex International Sulmona, Italy 13-Feb-17
Manufacturer of specialty nonwovens components designed to offer customized
hygiene premium materials. Undisclosed
Modern Dental Europe CDI Dental Malmö, Sweden 13-Feb-17 Provider of dental care products. 4.26
TPG Capital
Mediware
Information
Systems Lenexa, KS 9-Feb-17
Provider of enterprise software to healthcare and human service providers and
payers across acute, non-acute and community-based sites of care. Undisclosed
Valens GroWorks Island Green Cure
British Columbia,
Canada 9-Feb-17 Producer of marijuana drugs for medical purposes. 1.91
Weihai Weigao Equity
Investment
Management Company
Rad Source
Technologies Suwanee, GA 7-Feb-17
Provider of renewable, non-isotope, ionizing radiation replacements for self-
shielded gamma irradiators. Undisclosed
Quotient Clinical SeaView Research Miami, FL 6-Feb-17
Operator of a clinical research organization providing quality clinical
pharmacology testing and laboratory services to the pharmaceutical industry. Undisclosed
Finance Wales, Andrew
Beresford, Nicola
Watkins, Ian Corp,
Kevin Davies
Minerva
Laboratories
Cardiff, United
Kingdom 6-Feb-17 Manufacturer of earmolds and ultrasonic cleaning equipment. Undisclosed
Kirkman Group Rose Laboratories Bend, OR 3-Feb-17
Producer and seller of nutraceutical products intended to offer a full range of
chelated vitamins and food supplements. Undisclosed
Manufacturer of antibody diagnostics, imaging, therapeutics and affinity products
for biopharmaceutical manufacturing. Undisclosed
ICU Medical
Hospira (Infusion
Systems Business) Lake Forest, IL 3-Feb-17
Manufacturer of infusion and pain-management pumps designed to administer
intravenous medications and fluids to patients. 900.00
Ottobock
RSL Steeper
(BeBionic
Prosthetics
Division)
Leeds, United
Kingdom 2-Feb-17
Manufacturer of prosthetic hands designed to enable amputees to perform
everyday activities. Undisclosed
Specialists on Call NeuroCall Miami, FL 2-Feb-17 Provider of clinical telemedicine technology and services. Undisclosed
Compiled by: Morgan Reape
Source: Pitchbook 20
Monthly Healthcare Review
February 2017
Acquirer Target HQ Location Date DescriptionTransaction
Value (Millions)
Mergers and AcquisitionsThe following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous
month.
Ampersand Capital
Partners Corpus Medical Campbell, CA 2-Feb-17
Provider of contract development and manufacturing services focused on the
development and commercialization of innovative interventional medical devices,
catheter based-delivery systems and implants. Undisclosed
SpecialtyCare
Trident Health
Resources Dunedin, FL 1-Feb-17
Operator of a premiere perfusion services staffing company intended to provide
superior clinical care to the patient. Undisclosed
i3
Randall Data
System Plymouth, MI 1-Feb-17
Provider of custom accounting and inventory management services specializing in
the microcomputer market to a broad range of healthcare and healthcare-related
organizations. Undisclosed
Nordson Plas-Pak Industries Norwich, CT 1-Feb-17
Manufacturer of injection molded, single-use plastic dispensing syringes intended
to improve and diversify disposable plastic packaging. Undisclosed
Allergan LifeCell Somerville, NJ 1-Feb-17
Developer and marketer of soft tissue repair products for abdominal wall
reconstruction, blood cell preservation, cell reconstruction and plastic surgery. 2900.00
Ecolab Laboratoires Anios Lille, France 1-Feb-17
Manufacturer and marketer of antimicrobial liquids and disinfectants for hospitals
and clinics, healthcare professionals, dentists and industrial use. 798.85
Kaiser Permanente
Group Health
Cooperative (US) Seattle, WA 1-Feb-17
Provider of health plan administration services, such as medical coverage,
Medicare advantage plans and other related services. 1800.00
Cello Group Defined Health Florham Park, NJ 1-Feb-17
Provider of business development strategy consulting services intended to assist
clients in the pharmaceutical, biotech and healthcare investment industries. 9.00
